Ophthalmic biosimilars: Lessons from India.
作者信息
Sharma Ashish, Kumar Nilesh, Kuppermann Baruch D, Francesco Bandello, Lowenstein Anat
机构信息
Department of Vitreoretina, Lotus Eye Hospital and Institute, Coimbatore, Tamil Nadu, India.
Gavin Herbert Eye Institute, University of California, Irvine, CA, USA.
出版信息
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
Abstract
摘要
相似文献
1
Ophthalmic biosimilars: Lessons from India.眼科生物类似药：来自印度的经验教训。
Indian J Ophthalmol. 2019 Aug;67(8):1384-1385. doi: 10.4103/ijo.IJO_430_19.
2
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
3
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
4
Post-Ranibizumab injection endophthalmitis in aggressive posterior retinopathy of prematurity.早产儿后部进展性视网膜病变经雷珠单抗注射后的眼内炎。
Indian J Ophthalmol. 2019 Jun;67(6):967-969. doi: 10.4103/ijo.IJO_884_17.
5
The brave new world of biosimilars ('similar biologics') in India.印度生物类似药（“类似生物制品”）的全新世界。
Postgrad Med J. 2017 Oct;93(1104):577-579. doi: 10.1136/postgradmedj-2017-134806. Epub 2017 May 25.
6
Association of Acute Endophthalmitis With Intravitreal Injections of Corticosteroids or Anti-Vascular Growth Factor Agents in a Nationwide Study in France.在法国全国性研究中，急性眼内炎与玻璃体内注射皮质类固醇或抗血管生成因子药物的关联。
JAMA Ophthalmol. 2018 Dec 1;136(12):1352-1358. doi: 10.1001/jamaophthalmol.2018.3939.
7
Razumab -- the role of biosimilars for the treatment of retinal diseases.雷珠单抗——生物类似药在视网膜疾病治疗中的作用。
Drugs Today (Barc). 2021 Aug;57(8):499-505. doi: 10.1358/dot.2021.57.8.3284618.
8
Biosimilar ranibizumab in India- overview of phase 3 clinical trial designs.印度的生物类似药雷珠单抗——3期临床试验设计概述
Eye (Lond). 2024 Jul;38(10):1796-1798. doi: 10.1038/s41433-024-03001-8. Epub 2024 Mar 4.
9
Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center.同一天行双侧玻璃体内抗血管内皮生长因子注射：加拿大一大型视网膜中心的经验。
Ophthalmologica. 2019;242(1):1-7. doi: 10.1159/000499115. Epub 2019 Mar 29.
10
Incidence of post-intravitreal anti-VEGF endophthalmitis at Thammasat University Hospital.泰国国立法政大学医院玻璃体内注射抗VEGF药物后眼内炎的发病率。
J Med Assoc Thai. 2015 May;98(5):489-94.
引用本文的文献
1
Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.阿柏西普2毫克生物类似药——它们会引领全球抗血管内皮生长因子生物类似药领域吗？
Eye (Lond). 2025 Apr;39(6):1026-1027. doi: 10.1038/s41433-025-03732-2. Epub 2025 Feb 19.
2
Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study.糖尿病性黄斑水肿（DME）患者从阿柏西普转换为生物类似药雷珠单抗：（TRANSFORM-DME试验）一项多中心观察性研究。
Clin Ophthalmol. 2024 Nov 25;18:3449-3456. doi: 10.2147/OPTH.S500912. eCollection 2024.
3
Anti-VEGF Biosimilars for Retinal Diseases Survey 2023- India (Bio-INDAS) by the International Retina Biosimilar Study Group (Inter-BIOS Group) in collaboration with the Vitreo-Retinal Society of India (VRSI).国际视网膜生物类似药研究小组（国际生物类似药小组）与印度玻璃体视网膜协会（VRSI）合作开展的《2023年印度视网膜疾病抗VEGF生物类似药调查》（Bio-INDAS）
Eye (Lond). 2024 Dec;38(17):3392-3395. doi: 10.1038/s41433-024-03284-x. Epub 2024 Aug 26.
4
Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study.新生血管性年龄相关性黄斑变性患者从阿柏西普转换为生物类似药雷珠单抗的疗效观察（TRANSFORM试验）：一项多中心观察性研究
Clin Ophthalmol. 2024 Jun 24;18:1819-1828. doi: 10.2147/OPTH.S459085. eCollection 2024.
5
Intravitreal Anti-Vascular Endothelial Growth Factor Therapies for Retinal Disorders.用于视网膜疾病的玻璃体内抗血管内皮生长因子疗法
Pharmaceuticals (Basel). 2023 Aug 11;16(8):1140. doi: 10.3390/ph16081140.
6
Clinical Practice Update: Management of Infectious Endophthalmitis After Intravitreal Anti-VEGF Injection.临床实践更新：玻璃体内抗血管内皮生长因子注射后感染性眼内炎的管理
J Vitreoretin Dis. 2022 Sep 8;6(6):443-451. doi: 10.1177/24741264221116487. eCollection 2022 Nov-Dec.
7
Commentary: Biosimilars in the treatment of retinopathy of prematurity.评论：生物类似药在早产儿视网膜病变治疗中的应用
Indian J Ophthalmol. 2023 Feb;71(2):416-417. doi: 10.4103/ijo.IJO_2254_22.
8
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.糖尿病性黄斑水肿：当前认识、分子机制及治疗意义。
Cells. 2022 Oct 25;11(21):3362. doi: 10.3390/cells11213362.
9
A prospective, randomized, parallel group, double blind, multicenter study to compare the efficacy, safety and immunogenicity of Lupin's Ranibizumab with Lucentis in patients with neovascular age-related macular degeneration.一项前瞻性、随机、平行分组、双盲、多中心研究，旨在比较鲁宾的雷珠单抗与 Lucentis 在治疗新生血管性年龄相关性黄斑变性患者中的疗效、安全性和免疫原性。
Indian J Ophthalmol. 2022 Aug;70(8):3008-3014. doi: 10.4103/ijo.IJO_2118_21.
10
Retina: a unique subspecialty in the biosimilar landscape.视网膜：生物类似药领域中的一个独特亚专业。
Eye (Lond). 2022 Jun;36(6):1145-1146. doi: 10.1038/s41433-022-01984-w. Epub 2022 Feb 21.
本文引用的文献
1
Biotherapeutics and immunogenicity: ophthalmic perspective.生物疗法与免疫原性：眼科视角
Eye (Lond). 2019 Sep;33(9):1359-1361. doi: 10.1038/s41433-019-0434-y. Epub 2019 Apr 9.
2
Biosimilars in ophthalmology: "Is there a big change on the horizon?".眼科生物类似药：“即将迎来重大变革吗？”
Clin Ophthalmol. 2018 Oct 24;12:2137-2143. doi: 10.2147/OPTH.S180393. eCollection 2018.
3
Severe Ocular Inflammation Following Ranibizumab or Aflibercept Injections for Age-Related Macular Degeneration: A Retrospective Claims Database Analysis.雷珠单抗或阿柏西普注射治疗年龄相关性黄斑变性后发生的严重眼部炎症：一项回顾性索赔数据库分析
Ophthalmic Epidemiol. 2016;23(2):71-9. doi: 10.3109/09286586.2015.1090004. Epub 2016 Feb 8.
Zotero 插件